Swiss drug maker, Novartis is working on the mid-stage Phase IIb trial programme with the group Medicines for Malaria Venture to launch clinical trials of the first new antimalarial medicine – drug KAF156 for many years in nine countries across Africa and Asia.
According to Reuters, Initial tests suggest KAF156 has the potential to rapidly clear malaria infection, including resistant strains, as well as to block the transmission of the mosquito-borne malaria parasite.
KAF156, is an antimalarial designed to be used in combination with an improved formulation of the existing antimalarial lumefantrine.
“To build on the gains made against malaria since the turn of the century, we need new medicines that are effective across all types of resistance patterns and geographies, and that are easy to administer, especially to children,” said Dr David Reddy, CEO of MMV
According to World Health Organisation CLOSE TO 500,000 mostly children die from Malaria in Africa.